ArticleCancer discovery2025
Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer.
Abstract read
In one paragraph
Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window of opportunity for checkpoint inhibitor therapy in prostate cancer.Journal for immunotherapy of cancer · 2026Article
- Article
- Molecular Mechanisms and Immune Regulation in Prostate Cancer: A Review.International journal of molecular sciences · 2026Review
- Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Single-cell profiling of peripheral blood mononuclear cells in diverse men with prostate cancer reveals a fatal disease-associated immune signature.Cancer immunology research · 2026Article
- Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer.Nature reviews. Urology · 2026Review
- Multidimensional explanations and future perspectives on the limited efficacy of immunotherapy in prostate cancer.Asian journal of andrology · 2026Review
- Programmable mRNA 3'UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer.Nature biomedical engineering · 2026Article
- Review
- Striking the right balance with type I interferon signalling in cancer.Nature reviews. Cancer · 2026Review
- HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer.Prostate cancer and prostatic diseases · 2026Article
- GNL3 Orchestrates AR Transcriptional Programs to Drive Castration-Resistant Prostate Cancer and Immune Evasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- PARP inhibitors restore NK cell function via secretory crosstalk with tumor cells in prostate cancer.The Journal of clinical investigation · 2026Article
- Androgens are a Key Factor Affecting Immune Related Diseases.The world journal of men's health · 2026Review
- Genomic landscape and precision therapy in prostate cancer: current status and future directions.NPJ precision oncology · 2026Review
- MAPK ERK5 is a novel regulator of MHC-I in cancer cells.Cell communication and signaling : CCS · 2026Article
- The Multifaceted Role of Androgen Receptor Signaling in Immunity: Implications for Oncology.Molecular cancer research : MCR · 2026Review
- Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer.Journal of the National Cancer Center · 2026Review
- Tumor-Intrinsic PD-1 Regulatory Network Drives Lapatinib Resistance in HER2⁺ Breast Cancer: An Integrative Bioinformatics Analysis.Asian Pacific journal of cancer prevention : APJCP · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Lisa N ChesnerHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0009-0007-2779-8824
Fanny PolessoDepartment of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0003-1245-4563
Julie N GraffKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0002-5708-2794
Jessica E HawleyDepartment of Medicine, University of Washington, Seattle, Washington.ORCID 0000-0003-1720-5654
Alexis K SmithHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0009-0000-7291-0714
Arian LundbergHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-6630-2787
Rajdeep DasHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-9280-6076
Tanushree ShenoyHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-0653-6749
Martin SjöströmHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-2629-9966
Faming ZhaoDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-8238-3863
Ya-Mei HuDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-2575-1770
Simon LinderDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-3315-305X
William S ChenHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-3717-670X
Reed M HawkinsDepartment of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0001-8611-2588
Raunak ShresthaHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-1144-1413
Xiaolin ZhuHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-3221-595X
Adam FoyeHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-9910-9836
Haolong LiHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-8628-9698
Lisa M KimHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-2071-2000
Megha BhallaHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0009-0009-3380-624X
Thomas O'loughlinHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-4783-2352
Duygu Kuzuoglu-OzturkHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-1737-5020
Junjie T HuaHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-1197-1174
Michelle L BaduraHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-5325-8097
Scott WilkinsonGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-2613-8425
Shana Y TrostelGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0002-5929-2576
Andries M BergmanDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0001-5223-2549
Davide RuggeroHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-9444-5865
Charles G DrakeDepartment of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York.ORCID 0000-0001-9610-3677
Adam G SowalskyGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, Maryland.ORCID 0000-0003-2760-1853
Lawrence FongHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-6428-428X
Matthew R CooperbergHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-4339-6685
Wilbert ZwartDivision of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-9823-7289
Xiangnan GuanDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon.ORCID 0009-0003-4978-3093
Alan AshworthHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-1446-7878
Zheng XiaKnight Cancer Institute, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0003-3364-8324
David A QuigleyHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-4726-1473
Luke A GilbertHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-5854-0825
Felix Y Feng *Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-0963-7687
Amy E Moran *Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, Oregon.ORCID 0000-0003-1952-7737
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alan Ashworth · 1999 to 2026
$209.7MClinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MTRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1MPROMINENT - UCSFOT2CA278665 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALLAN BALMAIN · 2022 to 2026
$8.9MUCSF Specialized Programs of Research Excellence (SPOREs) in Prostate CancerP50CA275741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ERIC J SMALL · 2024 to 2026
$8.8MMechanisms of regulated translation control in cancer and its therapeutic implicationsR35CA242986 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RUGGERO, DAVIDE · 2019 to 2025
$6.4MDeterminants of response to cancer immunotherapyR35CA253175 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Lawrence Fong · 2021 to 2026
$5.8MMolecular Oncology Training ProgramT32CA203703 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Katherine D Crew, DAWN HERSHMAN · 2016 to 2026
$4.1MMolecular Mechanisms of Castration Resistant Prostate Cancer Recurrence & Therapeutic StrategiesR01CA227025 · NCI · WASHINGTON UNIVERSITY · PI FENG, FELIX YI-CHUNG, MAHAJAN, NUPAM P · 2019 to 2023
$2.8MA GENETIC INTERACTION MAP OF THE HUMAN NUCLEUSDP2CA239597 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GILBERT, LUKE · 2018 to 2018
$2.4MPORT (Portland Oral health Research Training)T90DE030859 · NIDCR · OREGON HEALTH & SCIENCE UNIVERSITY · PI WU, HUI · 2021 to 2025
$2.1MCharacterizing phenotype-associated subpopulations from single-cell sequencing dataR01GM147365 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Zheng Xia · 2023 to 2026
$1.2MAmerican Cancer Society (ACS) RP-19-, 181-, 01-RMCCancer Research UK (CRUK) OT2CA278665Conquer Cancer Foundation (CCF) 2019YIANational Cancer Institute (NCI) 1P50CA275741National Cancer Institute (NCI) 5R01CA227025National Cancer Institute (NCI) R01GM147365National Cancer Institute (NCI) R35CA242986National Cancer Institute (NCI) R35CA253175National Cancer Institute (NCI) T32CA203703NCATS NIH HHS UL1 TR001873NCI NIH HHS DP2 CA239597NCI NIH HHS OT2 CA278665NCI NIH HHS P30 CA082103NCI NIH HHS P50 CA097186NCI NIH HHS P50 CA275741NCI NIH HHS R01 CA227025NCI NIH HHS R35 CA242986NCI NIH HHS R35 CA253175NCI NIH HHS T32 CA203703NIDCR NIH HHS T90 DE030859NIGMS NIH HHS R01 GM147365Prostate Cancer Foundation (PCF)U.S. Department of Defense (DOD) HT9425-24-1-0506U.S. Department of Defense (DOD) W81XWH1910712U.S. Department of Defense (DOD) W81XWH2110046U.S. Department of Defense (DOD) W81XWH2110539U.S. Department of Defense (DOD) W81XWH-22-1-0833
Abstract
significanceImmunotherapy options for immune cold tumors, like prostate cancer, are limited. We show that AR downregulates MHCI expression/antigen presentation and that AR inhibition improves T-cell responses and tumor control. This suggests that treatments combining AR inhibitors and checkpoint blockade may improve tumor immune surveillance and antitumor immunity in patients.
Indexed as
Androgen Receptor AntagonistsHistocompatibility Antigens Class IProstatic NeoplasmsReceptors, AndrogenAnimalsCell Line, TumorHumansMaleMiceAndrogen Receptor AntagonistsHistocompatibility Antigens Class IReceptors, Androgen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.